ReWalk Robotics Ltd. (LFWD) AI Stock Analysis

ReWalk Robotics Ltd. is a medical device company that develops and commercializes advanced technologies designed to improve mobility and rehabilitation for individuals with physical and neurological conditions. Its product offerings include the ReWalk personal and rehabilitation exoskeleton devices for individuals with spinal cord injuries, the ReStore soft exo-suit for post-stroke lower limb recovery, and the AlterG Anti-Gravity System for physical therapy and athletic training. It also offers MyoCycle devices and the ReBoot personal soft exo-suit. Founded in 2001 and headquartered in Yokneam Illit, Israel, the company sells its products directly to healthcare institutions and individuals, as well as through third-party distributor partnerships.

Annual revenue grew from $6.0M in FY2021 to a peak of $25.7M in FY2024 before declining 14.1% to $22.0M in FY2025. Gross margin stood at 38.2% in FY2025, an improvement from 32.0% in FY2024. Operating margin improved from -212.1% in FY2021 to -76.7% in FY2025, while net income was -$19.9M compared to -$28.9M in FY2024. Over the 5-year period from FY2020 to FY2025, revenue achieved a compound annual growth rate of 38.1%. For the latest quarter ended June 30, 2026, revenue increased 15.7% year-over-year, while trailing twelve-month revenue reached $21.8M with a net profit margin of -141.3% and EPS of -$15.73.

As of June 30, 2026, ReWalk Robotics held $9.4M in cash and short-term investments against $11.1M in total debt, resulting in net debt of $1.6M. Shareholders' equity was $12.2M, total assets stood at $35.0M, and the current ratio was 2.33 with a debt-to-equity ratio of 0.91. Free cash flow was -$16.8M in FY2025, matching an operating cash flow of -$16.8M. Capital expenditures for FY2025 were $16,000, while the share count expanded by 276.2% over five years.

At a last close of $6.00, ReWalk Robotics has a market capitalization of $17.0M and an enterprise value of $17.2M. The stock trades at a price-to-sales multiple of 0.8x and an EV-to-EBITDA multiple of 1.0x, below the median of its US-listed Healthcare peers, which trade at 4.1x price-to-sales and 12.0x EV-to-EBITDA. Over the past year, LFWD shares declined 29.6%, while the S&P 500 (SPY) returned 16.8%. Over a 5-year period, the stock fell 94.7% compared to an 83.0% gain for the S&P 500.

Wall Street coverage consists of 1 Strong Buy and 1 Buy rating. The mean price target is $20.00, which is 233.3% above the last close of $6.00. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $25.2M and an EPS of -$5.02. For the following fiscal year, 2 analysts project revenue of $41.8M and an EPS of -$1.42. ReWalk Robotics has beaten EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 13, 2026.

This page is an AI-written research summary of ReWalk Robotics Ltd. (LFWD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LFWD income statement, LFWD balance sheet, LFWD key metrics, LFWD analyst forecast, LFWD chart. See the LFWD stock overview for the latest quote and news.